Cat. # | Size | Qty. | Price |
---|---|---|---|
90624S | 100 µl |
|
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 44.4 |
Source/Isotype | IgG1 |
Product Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Loading of prestained molecular weight markers (#59329, 10 µl/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 µl/lane) to determine molecular weights are recommended.
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 262
Human
Monoclonal antibody is produced by immunizing animals with full-length human recombinant SERPINB3 protein.
SERPINB3 (Serpin Family B Member 3) or SCCA1 (Squamous Cell Carcinoma Antigen 1) belongs to the serpin family and inhibits papain-like cysteine proteases (1). SERPINB3 is unique to the other serpins, as it lacks inhibitory activity against serine proteases but has inhibitory activity against papain-like cysteine proteases cathepsins K, L, and S (1,2). It may function as an inhibitor to modulate the host immune response against tumor cells and can act as a UV-induced apoptosis inhibitor by suppressing the activity of c-Jun NH2-terminal kinase 1 (JNK1) (1,3). SERPINB3 is expressed in normal squamous epithelium and in several organs, including epithelium of the tongue, esophagus, uterine cervix and vagina, Hassall’s corpuscles of the thymus, and some areas of the skin (4). SERPINB3 has been found to be overexpressed and implicated in several types of cancer, including hepatocellular carcinoma (HCC), lung, ovarian, and breast cancer (5-8). It is also overexpressed and implicated in hepatoblastoma, autoimmune disorders, lung fibrosis, cholesteatoma, and skin disease (9-13).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.